Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

CytRx granted U.S. Patent for bafetinib

CytRx granted U.S. Patent for bafetinib

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

EpiCept provides update on post-approval commitments requested by EMA for Ceplene

EpiCept provides update on post-approval commitments requested by EMA for Ceplene

Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010

Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010

Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010

New multicenter trial achieves 71% survival in AML children

New multicenter trial achieves 71% survival in AML children

Chemical changes in genetic material regulate activity of many genes

Chemical changes in genetic material regulate activity of many genes

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

Alcohol consumption during pregnancy can increase risk of AML in children

Alcohol consumption during pregnancy can increase risk of AML in children

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

EpiCept's first Ceplene commercial shipment to the EU triggers $2M milestone payment from Meda

EpiCept's first Ceplene commercial shipment to the EU triggers $2M milestone payment from Meda

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Update on BioSante cancer vaccine portfolio to be presented at BIO International Convention

Update on BioSante cancer vaccine portfolio to be presented at BIO International Convention

Study examines world-wide use of HSCT

Study examines world-wide use of HSCT

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.